81.   The possible therapeutic effect of a specific receptor antagonist in inflammatory bowel disease remains to be evaluated.

82.   Pronounced changes have been found in gut neuropeptides in patients with inflammatory bowel disease.

83.   Corticosteroids are still the most effective treatment for active inflammatory bowel disease, but side effects are common and dose related.

84.   Its potential use in inflammatory bowel disease deserves clinical trials.

85.   Although hitherto largely used to localise infection and inflammation, preliminary experience with this tracer as a leucocyte label in inflammatory bowel disease has been encouraging.

86.   The use of radiolabelled leucocytes to localise and estimate disease activity in inflammatory bowel disease provides an objective technique for the assessment of disease activity.

87.   Variations in the uptake of labelled leucocytes in these organs have been reported and patients with inflammatory bowel disease may have associated hyposplenism which may affect the splenic uptake.

88.   Diagnosis is made from features on direct cholangiography indistinguishable from those of primary sclerosing cholangitis, but there is no link with inflammatory bowel disease.

89.   Patients with gall stones or established inflammatory bowel disease were excluded.

90.   These findings suggest that in active inflammatory bowel disease, an increased biosynthesis might coexist with an increased consumption of polyunsaturated fatty acids.